Zobrazeno 1 - 10
of 696
pro vyhledávání: '"Peter, Doshi"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Breuer T; GSK Vaccines, 20 Avenue Fleming, 1300 Wavre, Belgium., Bauchau V; GSK Vaccines, 20 Avenue Fleming, 1300 Wavre, Belgium., Poplazarova T; GSK Vaccines, 20 Avenue Fleming, 1300 Wavre, Belgium., Stegmann JU; GSK Vaccines, 20 Avenue Fleming, 1300 Wavre, Belgium.
Publikováno v:
BMJ (Clinical research ed.) [BMJ] 2018 Oct 03; Vol. 363, pp. k4116. Date of Electronic Publication: 2018 Oct 03.
Publikováno v:
BMJ. :k4116
We are writing to respond to The BMJ ’s feature article about the Pandemrix vaccine.”1 Our response focuses on some of the statements in the article as well the methodology on which the major premise of the article is based. The statement by The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80d5d6fe47051a9e9d5a19a1d010f78a
https://doi.org/10.1136/bmj.k4116
https://doi.org/10.1136/bmj.k4116
Autor:
Florence Bourgeois, Peter Doshi, Kyungwan Hong, Tom Jefferson, Mark Jones, Haeyoung Lee, Anisa Rowhani-Farid, Larissa Shamseer, O’Mareen Spence
Publikováno v:
mSphere, Vol 5, Iss 6 (2020)
Externí odkaz:
https://doaj.org/article/bbd71c70e491469e9b2e758d9cde53e4
Autor:
Alex Hodkinson, Kristina Charlotte Dietz, Carol Lefebvre, Su Golder, Mark Jones, Peter Doshi, Carl Heneghan, Tom Jefferson, Isabelle Boutron, Lesley Stewart
Publikováno v:
Systematic Reviews, Vol 7, Iss 1, Pp 1-12 (2018)
Abstract Background Clinical study reports (CSRs) are produced for marketing authorisation applications. They often contain considerably more information about, and data from, clinical trials than corresponding journal publications. Use of data from
Externí odkaz:
https://doaj.org/article/80615f9e14c4416d80bb7335cdb1879f
Publikováno v:
Trials, Vol 19, Iss 1, Pp 1-5 (2018)
Abstract Background Participants are recruited into clinical trials under the assumption that the research will contribute to medical knowledge. Therefore, non-publication trials—and, more recently, lack of data sharing—are widely considered to v
Externí odkaz:
https://doaj.org/article/0553c542d0464aab859ecf03f21847c9
Publikováno v:
Journal of Evaluation in Clinical Practice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a763370fa6d154f3044381dcd230176e
https://doi.org/10.1111/jep.13839
https://doi.org/10.1111/jep.13839
Publikováno v:
BMJ Evidence-Based Medicine. 27:199-205
Summary box Access to data for drugs and vaccines has historically been fairly limited to journal article publications and hard-to-access and difficult to read regulatory reports.1 But the past decade has witnessed strides in clinical trial data tran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2118e5c2b76f66c63c92fbf5f36306ed
https://doi.org/10.1136/bmjebm-2021-111735
https://doi.org/10.1136/bmjebm-2021-111735